Navigation Links
Aspirin May Protect Against Colorectal Cancer -- But Only in Certain People
Date:3/11/2011

FRIDAY, March 11 (HealthDay News) -- Taking aspirin to protect against colorectal cancer may be effective, but mostly in people at increased risk for the disease due to elevated levels of an inflammatory biomarker in their blood, according to a new study.

Previous research has found that people who take aspirin or other nonsteroidal anti-inflammatory drugs (NSAIDs) have a reduced risk of colorectal cancer. Other studies have noted that inflammation contributes to the development of conditions such as cardiovascular disease and several types of cancer.

In this new study, researchers at Massachusetts General Hospital and the Dana-Farber Cancer Institute found that elevated baseline levels of an inflammatory marker called "soluble tumor necrosis factor receptor-2 (sTNFR-2)" were associated with increased risk of colorectal cancer and also predicted who might benefit from taking aspirin or other NSAIDs, such as ibuprofen or naproxen.

The researchers analyzed data from 280 participants in the Nurses' Health Study who were cancer-free when they provided a blood sample in 1989 and 1990, but developed colorectal cancer over the next 14 years. These patients were compared to 555 age-matched participants who did not develop colorectal cancer.

The researchers analyzed baseline levels of three inflammatory markers -- sTNFR-2, c-reactive protein (CRP), and interleukin-6 (IL-6). There was no association between levels of CRP or IL-6 and risk of developing colorectal cancer. But people with the highest levels of sTNFR-2 were 60 percent more likely to develop colorectal cancer than those with the lowest levels of the factor.

The researchers also found that the reduced risk of colorectal cancer associated with regular use of aspirin or other NSAIDs was primarily seen among people with high baseline levels of sTNFR-2.

The study appears in the March issue of the journal Gastroenterology.

"These findings suggest that a blood biomarker may be helpful in deciding whether individuals should take aspirin or NSAIDs to reduce their cancer risk," lead author Dr. Andrew Chan, of the gastrointestinal unit at Massachusetts General Hospital, said in a hospital news release.

"They also indicate that chronic inflammatory pathways are quite complex, and further studies are needed to understand which facets of the inflammatory response are most associated with the development of colorectal cancer," he added.

More information

The U.S. National Cancer Institute has more about colorectal cancer prevention.

-- Robert Preidt

SOURCE: Massachusetts General Hospital, Dana-Farber Cancer Institute, news release, March 9, 2011


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Aspirins ability to protect against colorectal cancer may depend on inflammatory pathways
2. Small bowel blood flow in healthy subjects receiving low-dose aspirin
3. Low-Dose Aspirin Boosts Accuracy of Colon Cancer Test
4. Low-dose aspirin reduces death rates from range of cancers by between 20 and 30 percent
5. Daily Aspirin Linked to Steep Drop in Cancer Risk
6. Bleeding Risk With Plavix-Aspirin Regimen May Be Serious
7. Aspirin May Help Patients Beat Prostate Cancer
8. Aspirin, Statins May Reduce Problems After Heart Surgery
9. IV Aspirin Drip Appears to Be Safe, Effective for Migraine
10. Low-Dose Aspirin May Reduce Colon Cancer Risk
11. Can aspirin prolong a healthy life?
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Aspirin May Protect Against Colorectal Cancer -- But Only in Certain People
(Date:6/28/2017)... ... June 28, 2017 , ... ... communities throughout the greater Cincinnati metropolitan area, is teaming up with the local ... families with children receiving treatment in nearby hospitals. , Ronald McDonald House of ...
(Date:6/27/2017)... ... 2017 , ... Harbour , a DAO (decentralized autonomous organization) that harnesses ... released their technical specifications . , 2017 has seen an explosion of token ... determining which offerings will garner the greatest ROI. Dean Eigenmann, Co-founder and CEO of ...
(Date:6/27/2017)... , ... June 27, 2017 , ... From June 20-22, ... three-day event was held in Syracuse, New York, where EarQ is headquartered. , ... how to connect with today’s savvy consumer, and the latest in hearing technology. ...
(Date:6/27/2017)... New York, NY (PRWEB) , ... June 27, ... ... communications and marketing experts to contribute to an upcoming case studies guidebook. This ... or her organization. , This book will include articles, case studies and how-to’s ...
(Date:6/27/2017)... ... ... Hammer Strength, the world’s leading performance strength training brand, and the National ... the NBSCA Strength & Conditioning Coach of the Year. , In its 11th ... select the coach who embodies the highest level of excellence and outstanding service to ...
Breaking Medicine News(10 mins):
(Date:6/1/2017)... BLUE BELL, Pa. , June 1, 2017 /PRNewswire/ ... Nutriceuticals (PRN) and Veterinarian Recommended Solutions (VRS), and KD ... direct investment in Nutriceutical Holdings by KD Pharma Group. ... Nutriceutical Holdings with the option to acquire the entire ... ideal partner in KD. They are committed to growing ...
(Date:5/30/2017)... AVIV, Israel , May 30, 2017 ... stage pharmaceutical Company specializing in the development of ... will present a company overview at three upcoming ... The 7th Annual LD Micro Invitational: ... Date:                     ...
(Date:5/26/2017)... , May 25, 2017  In response to the ... , Direct Relief is working with Pfizer to make ... at no cost to community health centers, free and ... nationwide. "Pfizer has a long-standing commitment ... and ensuring patient safety through educational activities," said ...
Breaking Medicine Technology: